COSENTYX
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSENTYX (secukinumab) is a fully human monoclonal antibody that selectively targets and inhibits interleukin-17A, a key cytokine in inflammatory and autoimmune disease pathways. It is approved for multiple indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other IL-17A-driven conditions. The drug works by blocking IL-17A signaling, thereby reducing inflammatory responses in affected tissues.
Growth
COSENTYX is in active growth phase with moderate competitive pressure (30%), signaling expanding team investments and revenue-generation opportunities in commercial and medical affairs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Started Dec 2025
76 enrolled
Hidradenitis SuppurativaPediatric Plaque PsoriasisJuvenile Idiopathic Arthritis
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
Started May 2025
153 enrolled
Plaque Psoriasis
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Started Mar 2025
77 enrolled
Hidradenitis Suppurativa (HS)
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
Started Jan 2024
172 enrolled
Healthy Male Subjects
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Started Oct 2022
502 enrolled
Plaque Psoriasis
Worked on COSENTYX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.